Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
Braz. j. med. biol. res
;
43(6): 580-584, June 2010. ilus
Article
Dans Anglais
| LILACS
| ID: lil-548265
ABSTRACT
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3 percent of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Pipérazines
/
Pyrimidines
/
Leucémie myéloïde chronique BCR-ABL positive
/
Antinéoplasiques
Limites du sujet:
Enfant
/
Enfant d'âge préscolaire
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Braz. j. med. biol. res
Thème du journal:
Biologie
/
Médicament
Année:
2010
Type:
Article
Pays d'affiliation:
Brésil
/
Espagne
Institution/Pays d'affiliation:
Hospital Universitario de Salamanca/ES
/
Universidade Federal do Rio de Janeiro/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS